DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

BDX·Becton, Dickinson and Company

$.
+. (+.%)
After Hours
High
$153.24
Open
$151.78
Market Cap
41.65B
52W High
$187.35
Low
$150.70
P. Close
$151.16
P/E
36.60
52W Low
$127.59
Fwd P/E
11.28
DailyIQ Est.
-
Technical Score (1D)
50
NEUTRAL
News Sentiment
75
BULLISH
Becton, Dickinson reported a strong Q1 earnings beat, with revenue and net income exceeding expectations, prompting management to lift its full‑year earnings forecast. The earnings surprise and upward revision have positioned BDX as a more attractive valuation relative to peers, which is why Jim Cramer highlighted it as a buying window. The company’s robust performance is driven by continued demand for its medical devices and supply chain solutions, reinforcing its growth trajectory over the past five years. However, Cramer cautioned that rising AI‑related spending could create short‑term headwinds for the broader healthcare supply chain sector, potentially tempering momentum. Over the next 1–10 trading days, investors should monitor BDX’s guidance for any further adjustments, as the company’s earnings outlook is a key driver of short‑term price action. Additionally, watch for any updates on the company’s pipeline of new products, as successful launches could sustain the upward trajectory. Market participants will also be attentive to broader healthcare sector sentiment, especially any shifts in AI spending that could affect supply chain dynamics. Finally, keep an eye on the company’s quarterly earnings release schedule, as early indications of revenue growth or cost pressures will influence investor sentiment.
Earnings Summary
Becton, Dickinson and Company (BDX), a global medical technology firm, focuses on medical supplies, connected care, biopharma systems, and interventional and life sciences, delivering products such as vascular access devices and laboratory equipment. Operating within the medical instruments and supplies sector, BDX has demonstrated steady revenue growth, with Q4 2024 revenue of $5.168 billion, rising to $5.272 billion in Q1 2025, $5.509 billion in Q2 2025, and $5.890 billion in Q3 2025, before a slight decline to $5.252 billion in Q1 2026 and $4.714 billion in Q2 2026. In the last two quarters, the company’s EPS moved from $3.35 in Q1 2025, beating the $3.28051 estimate, to $3.68 in Q2 2025, surpassing the $3.4023 forecast, and then fell to $2.91 in Q1 2026, missing the $3.31222 estimate, before rising to $2.90 in Q2 2026, exceeding the $2.77494 expectation; this pattern of three out of four beats underscores a generally resilient earnings profile. Historically, BDX’s revenue has trended upward each quarter through Q3 2025, with EPS consistently beating analyst expectations except for the Q1 2026 miss, indicating a stable yet slightly volatile earnings trajectory. Recent news reports that BDX has issued a fiscal outlook projecting currency‑neutral revenue growth in the low single‑digit range, emphasizing cost discipline amid currency volatility, and that the company is sharpening focus on its urology and infection prevention divisions to drive growth; these strategic moves suggest a deliberate effort to sustain margins while pursuing incremental sales. Investors should watch for updates on currency hedging strategies, supply‑chain constraints, and pricing power, as changes in these areas could affect the company’s revenue projections and margin outlook, and should also monitor management commentary on the execution of its focused strategy in urology and infection prevention, which will be key to assessing future performance.

EPS

EstBeatMiss
$2.60$2.98$3.37$3.75$4.14Q1'25Q2'25Q3'25Q1'26Q2'26Q4'25
QtrEstActual+/−
Q4'25$2.81 - -
Q2'26$2.77$2.90+4.5%
Q1'26$3.31$2.91-12.1%
Q3'25$3.91$3.96+1.1%
Q2'25$3.40$3.68+8.2%
Q1'25$3.28$3.35+2.1%

Revenue

EstBeatMiss
$4.5B$4.9B$5.3B$5.7B$6.1BQ1'25Q2'25Q3'25Q1'26Q2'26Q4'25
QtrEstActual+/−
Q4'25$5.2B - -
Q2'26$4.7B$4.7B-0.0%
Q1'26$5.5B$5.3B-5.0%
Q3'25 - $5.9B -
Q2'25 - $5.5B -
Q1'25 - $5.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BDX Stock Snapshot

BDX is currently trading at $151.16, giving Becton, Dickinson and Company a market cap of 41.65B and a P/E ratio of 36.6. Today's range spans $150.70–$153.24, with shares opening at $151.78 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 50/100 (HOLD) with a news sentiment reading of 75/100.

Over the past year BDX has traded between $127.59 and $187.35 - the current price is +18.5% off the 52-week low and -19.3% from the high.

BDX is in a holding pattern - 50/100 technical score, HOLD signal, price at $151.16 (in the lower half of its 52-week range), sentiment bullish at 75/100. (P/E: 36.6) At 41.65B in Healthcare market cap, HOLD phases like this are where the thesis is re-evaluated and position sizing decisions get made by both longs and shorts. Annual range: $127.59–$187.35. The next catalyst, not the current setup, determines the exit from this range.

The 52-week range of $127.59–$187.35 for BDX provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $151.16 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 50/100 and bullish news backdrop (75/100) don't break the tie yet, but they narrow the probability distribution toward the upside.